Subcommittee E56.08 on Nano-Enabled Medical Products
Matching Standards Under the Jurisdiction of E56.08 by Status
- E3238-20 Standard Test Method for Quantitative Measurement of the Chemoattractant Capacity of a Nanoparticulate Material
in vitro - E3275-21 Standard Guide for Visualization and Identification of Nanomaterials in Biological and Nonbiological Matrices Using Darkfield Microscopy/Hyperspectral Imaging (DFM/HSI) Analysis
- E3297-21 Standard Test Method for Lipid Quantitation in Liposomal Formulations Using High Performance Liquid Chromatography (HPLC) with a Charged Aerosol Detector (CAD)
- -See also WK85364 proposed Revision
- E3323-22 Standard Test Method for Lipid Quantitation in Liposomal Formulations Using High Performance Liquid Chromatography (HPLC) with an Evaporative Light-Scattering Detector (ELSD)
- -See also WK85365 proposed Revision
- E3324-22 Standard Test Method for Lipid Quantitation in Liposomal Formulations Using Ultra-High-Performance Liquid Chromatography (UHPLC) with Triple Quadrupole Mass Spectrometry (TQMS)
- -See also WK85363 proposed Revision
- E3351-22 Standard Test Method for Detection of Nitric Oxide Production
In Vitro
- WK60553 Evaluating the Impact of Nanomaterials on Phagocytic Function in Vitro
- WK67980 Quantifying Poly(ethylene glycol) Coating on the Surface of Gold Nanostructured Materials Using High Performance Liquid Chromatography with Evaporative Light Scattering Detection (HPLC/ELSD)
- WK69051 Assessing the Activation of the Complement System in Human Plasma Through Quantification of iC3b Concentration by ELISA,
- WK75607 Characterization of Encapsulation, Extraction, and Analysis of RNA in Lipid Nanoparticle Formulations for Drug Delivery
- WK86057 New Standard Test Method for Measuring Sulfate and Ammonium Ion Concentrations in Liposome Drug Formulations
- WK86056 Measuring In Vitro Drug Release from Liposomal Drug Formulations.